(Q35065186)

English

Novel antifolate drugs

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

6 August 2017

1 reference

Europe PubMed Central

Novel antifolate drugs (English)

1 reference

Europe PubMed Central

6 August 2017

author name string

W Thomas Purcell

1

1 reference

Europe PubMed Central

6 August 2017

David S Ettinger

2

1 reference

Europe PubMed Central

6 August 2017

publication date

1 March 2003

1 reference

Europe PubMed Central

6 August 2017

Current Oncology Reports

1 reference

Europe PubMed Central

6 August 2017

5

1 reference

Europe PubMed Central

6 August 2017

114-125

1 reference

Europe PubMed Central

6 August 2017

2

1 reference

Europe PubMed Central

6 August 2017

https://scigraph.springernature.com/pub.10.1007/s11912-003-0098-3

0 references

Pemetrexed in the treatment of selected solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS11912-003-0098-3

21 January 2018

Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase

1 reference

https://api.crossref.org/works/10.1007%2FS11912-003-0098-3

21 January 2018

Methotrexate transport and resistance.

1 reference

https://api.crossref.org/works/10.1007%2FS11912-003-0098-3

21 January 2018

Future directions in the development of pemetrexed

1 reference

https://api.crossref.org/works/10.1007%2FS11912-003-0098-3

21 January 2018

Phase I trials of pemetrexed

1 reference

https://api.crossref.org/works/10.1007%2FS11912-003-0098-3

21 January 2018

Role of surgery in the treatment of bilio-pancreatic cancer: the European experience

1 reference

https://api.crossref.org/works/10.1007%2FS11912-003-0098-3

21 January 2018

A rationale for the clinical development of the thymidylate synthase inhibitor ZD9331 in ovarian and other solid tumours

1 reference

https://api.crossref.org/works/10.1007%2FS11912-003-0098-3

21 January 2018

The human glycinamide ribonucleotide transformylase domain: purification, characterization, and kinetic mechanism

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ALIMTA (pemetrexed disodium, LY231514, MTA): clinical experience in non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alimta (pemetrexed disodium): a multitargeted antifolate for the treatment of mesothelioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pemetrexed disodium (Eli Lilly).

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pemetrexed (Alimta) and gemcitabine in breast cancer patients previously treated with anthracyclines and taxanes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antifolate resistance mechanisms from bacteria to cancer cells with emphasis on parasites.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pemetrexed in patients with gastrointestinal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New antifolates in clinical development

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pemetrexed: a multitargeted antifolate (ALIMTA, LY-231514).

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Folate-binding triggers the activation of folylpolyglutamate synthetase

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activity of pemetrexed (alimta), a new antifolate, against non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine and pemetrexed disodium combinations in vitro and in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacogenetics and folate metabolism -- a promising direction

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ZD-9331 AstraZeneca

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pemetrexed disodium, a novel antifolate with multiple targets

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antifolates: the next generation

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Folate status and the safety profile of antifolates

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of impaired renal function on the pharmacokinetics and toxicity of i.v. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enzymatic assays for 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline, a promising new "nonclassical" antifolate

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Raltitrexed plus oxaliplatin as first-line chemotherapy in metastatic colorectal carcinoma: a multicentric phase II trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine and Pemetrexed disodium in treating breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetic study of LY309887: a specific inhibitor of purine biosynthesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor resistance to antimetabolites

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antifolates targeting purine synthesis allow entry of tumor cells into S phase regardless of p53 function

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antifolate resistance and its circumvention by new analogues.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Result of two randomized trials comparing nolatrexed (Thymitaq) versus methotrexate in patients with recurrent head and neck cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Current understanding of methotrexate pharmacology and efficacy in acute leukemias. Use of newer antifolates in clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trials.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antifolates in clinical development.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The pemetrexed/gemcitabine combination in pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine and pemetrexed (Alimta) in thoracic cancers: present and future perspectives. Introduction and current controversies

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synergistic interactions among antifolates

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine/Alimta in locally advanced or metastatic non-small-cell lung cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Edatrexate, an antifolate with antitumor activity: a review

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A novel folate transport activity in human mesothelioma cell lines with high affinity and specificity for the new-generation antifolate, pemetrexed.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanisms of methotrexate resistance in acute leukemia. Decreased transport and polyglutamylation

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Raltitrexed: current clinical status and future directions

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MTA, a novel multitargeted antifolate, from preclinical to phase I and beyond: summary and conclusions

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synthesis and biological evaluation of poly-gamma-glutamyl metabolites of 10-deazaaminopterin and 10-ethyl-10-deazaaminopterin.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Integrated analysis of overall survival in two randomised studies comparing 5-fluorouracil/leucovorin with or without trimetrexate in advanced colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular and cellular biology of the human reduced folate carrier

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Methotrexate pharmacology and resistance in childhood acute lymphoblastic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of the antipurine antifolate lometrexol (DDATHF) with folinic acid rescue.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thymitaq (Zarix).

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New Antifolates: Pharmacology and Clinical Applications.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase/inosine 5'-monophosphate cyclohydrolase. A bifunctional protein requiring dimerization for transformylase activity but not for cyclohydrolase activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Folate and antifolate pharmacology.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The emerging role of antifolates in the treatment of malignant pleural mesothelioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanisms of methotrexate resistance in osteosarcoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II trial of edatrexate, vinblastine, adriamycin, cisplastin, and filgrastim (EVAC/G-CSF) in patients with non-small-cell carcinoma of the lungs: a North Central Cancer Treatment Group Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pemetrexed combination therapy in the treatment of non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pemetrexed: a promising new treatment for breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pemetrexed: translational research in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514

1 reference

https://pubmed.ncbi.nlm.nih.gov/12583828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11912-003-0098-3

1 reference

Europe PubMed Central

6 August 2017

1 reference

Europe PubMed Central

6 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35065186&oldid=1967016113"